Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H
Second Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Am J Gastroenterol. 2000 Apr;95(4):1041-50. doi: 10.1111/j.1572-0241.2000.01979.x.
Hepatic iron deposition has been reported in chronic hepatitis C (CH-C), and iron-induced lipid peroxidation may be involved in the pathogenesis of CH-C. The aims of the present study were: 1) to determine whether patients with CH-C have evidence of enhanced hepatic lipid peroxidation and to evaluate its relation to iron status, compared with that in patients with chronic hepatitis B (CH-B); and 2) to assess the effect of interferon (IFN) therapy on hepatic iron and lipid peroxidation.
In the liver biopsies of 40 patients with CH-C and 26 patients with CH-B, immunohistochemical detection of 4-hydroxy-2-nonenal (HNE)-protein adducts for evaluation of lipid peroxidation was performed, and hepatic iron status was biochemically and histologically assessed. In 16 CH-C patients with normal serum transaminases and undetectable serum HCV-RNA >6 months after the end of IFN treatment (responders) and in 11 nonresponders, hepatic HNE-protein adducts and siderosis were evaluated in pre- and posttreatment liver biopsies.
Hepatocytic HNE-protein adducts and iron deposits were more abundant in the patients with CH-C than in those with CH-B. No correlation was found between the levels of hepatocytic HNE-protein adducts and hepatic iron status in either of the two groups. In the responders to IFN treatment for CH-C, hepatocytic HNE-protein adducts disappeared or attenuated with improvement of hepatic siderosis after the treatment, whereas IFN treatment did not improve hepatocytic expression of HNE-protein adducts and hepatic siderosis in the nonresponders.
Patients with CH-C have evidence of enhanced hepatic iron accumulation and lipid peroxidation compared to those with CH-B. In CH-C, hepatic siderosis and lipid peroxidation are improved with successful IFN treatment. These results suggest that hepatic lipid peroxidation and iron may potentially play contributory roles in the pathogenesis of CH-C.
据报道,慢性丙型肝炎(CH-C)患者存在肝脏铁沉积,铁诱导的脂质过氧化可能参与CH-C的发病机制。本研究的目的是:1)与慢性乙型肝炎(CH-B)患者相比,确定CH-C患者是否有肝脏脂质过氧化增强的证据,并评估其与铁状态的关系;2)评估干扰素(IFN)治疗对肝脏铁和脂质过氧化的影响。
对40例CH-C患者和26例CH-B患者的肝脏活检组织进行免疫组织化学检测,以检测4-羟基-2-壬烯醛(HNE)-蛋白加合物来评估脂质过氧化,并对肝脏铁状态进行生化和组织学评估。在16例血清转氨酶正常且在IFN治疗结束后>6个月血清HCV-RNA检测不到的CH-C患者(应答者)和11例无应答者中,对治疗前和治疗后的肝脏活检组织评估肝脏HNE-蛋白加合物和铁沉积情况。
CH-C患者的肝细胞HNE-蛋白加合物和铁沉积比CH-B患者更丰富。在两组患者中,肝细胞HNE-蛋白加合物水平与肝脏铁状态之间均未发现相关性。在CH-C的IFN治疗应答者中,治疗后随着肝脏铁沉积的改善,肝细胞HNE-蛋白加合物消失或减少,而在无应答者中,IFN治疗并未改善肝细胞HNE-蛋白加合物的表达和肝脏铁沉积。
与CH-B患者相比,CH-C患者有肝脏铁蓄积和脂质过氧化增强的证据。在CH-C中,成功的IFN治疗可改善肝脏铁沉积和脂质过氧化。这些结果表明,肝脏脂质过氧化和铁可能在CH-C的发病机制中起一定作用。